Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2021 | Challenges of CAR-T bridging to allo-SCT

Livio Pagano • 8 Mar 2021
EBMT 2021

Livio Pagano, MD, Catholic University of Sacred Heart, Rome, Italy, discusses challenges associated with using chimeric antigen receptor T-cell (CAR-T) therapy as a bridging therapy to allogeneic stem cell transplantation (allo-SCT), outlining the increased risk of fungal infection. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

Disclosures

Prof. Livio Pagano, MD, discloses connections to Jazz Pharmaceuticals, Janssen, Novartis, Gilead, Menarini, Cidara Therapeutics, Stemline, Pfizer and MSD.

More from Livio Pagano

2:23
The incidence of fungal disease in patients with FLT3-mutated AML treated with midostaurin
Livio Pagano • 16 Mar 2023
2:15
How COVID-19 has impacted patients with hematological malignancies
Livio Pagano • 16 Mar 2023
2:21
Infectious complications & outcomes of patients with AML receiving treatment with HMAs ± venetoclax
Livio Pagano • 16 Mar 2023
2:29
Unmet clinical needs in BPDCN: improving diagnosis and treatment approaches
Livio Pagano • 16 Mar 2023
The content of VJHemOnc is intended for healthcare professionals